Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CNCT19 anti-CD19 CAR-T cell injection for relapsed or refractory non-Hodgkin lymphoma
CTR20201986Phase 2Active
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Nov 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in non-Hodgkin lymphoma (NHL), sponsored by Juventas Cell Therapy Ltd.. Started Nov 2020; status: active.
02
Drugs
inaticabtagene autoleucel
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20201986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201986.